455 related articles for article (PubMed ID: 25226850)
21. Budesonide Oral Suspension Improves Symptomatic, Endoscopic, and Histologic Parameters Compared With Placebo in Patients With Eosinophilic Esophagitis.
Dellon ES; Katzka DA; Collins MH; Hamdani M; Gupta SK; Hirano I;
Gastroenterology; 2017 Mar; 152(4):776-786.e5. PubMed ID: 27889574
[TBL] [Abstract][Full Text] [Related]
22. Esophageal eosinophilic infiltration responds to proton pump inhibition in most adults.
Molina-Infante J; Ferrando-Lamana L; Ripoll C; Hernandez-Alonso M; Mateos JM; Fernandez-Bermejo M; Dueñas C; Fernandez-Gonzalez N; Quintana EM; Gonzalez-Nuñez MA
Clin Gastroenterol Hepatol; 2011 Feb; 9(2):110-7. PubMed ID: 20920599
[TBL] [Abstract][Full Text] [Related]
23. Elevated IL-33 expression is associated with pediatric eosinophilic esophagitis, and exogenous IL-33 promotes eosinophilic esophagitis development in mice.
Judd LM; Heine RG; Menheniott TR; Buzzelli J; O'Brien-Simpson N; Pavlic D; O'Connor L; Al Gazali K; Hamilton O; Scurr M; Collison AM; Mattes J; Allen KJ; Giraud AS
Am J Physiol Gastrointest Liver Physiol; 2016 Jan; 310(1):G13-25. PubMed ID: 26514775
[TBL] [Abstract][Full Text] [Related]
24. Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial.
Dohil R; Newbury R; Fox L; Bastian J; Aceves S
Gastroenterology; 2010 Aug; 139(2):418-29. PubMed ID: 20457157
[TBL] [Abstract][Full Text] [Related]
25. The role of proton pump inhibitor therapy in the management of eosinophilic esophagitis.
Molina-Infante J; Prados-Manzano R; Gonzalez-Cordero PL
Expert Rev Clin Immunol; 2016 Sep; 12(9):945-52. PubMed ID: 27097787
[TBL] [Abstract][Full Text] [Related]
26. Circulating immunome fingerprint in eosinophilic esophagitis is associated with clinical response to proton pump inhibitor treatment.
Ugalde-Triviño L; Molina-Jiménez F; H-Vázquez J; Relaño-Rupérez C; Arias-González L; Casabona S; Pérez-Fernández MT; Martín-Domínguez V; Fernández-Pacheco J; Lucendo AJ; Bernardo D; Santander C; Majano P
Front Immunol; 2024; 15():1374611. PubMed ID: 38646544
[TBL] [Abstract][Full Text] [Related]
27. Pharmacologic Treatment of Eosinophilic Esophagitis: An Update.
Schoepfer AM; Straumann A; Safroneeva E
Gastrointest Endosc Clin N Am; 2018 Jan; 28(1):77-88. PubMed ID: 29129301
[TBL] [Abstract][Full Text] [Related]
28. Eosinophilic Esophagitis and Esophageal Granular Cell Tumor: An Unexpected Association.
Riffle ME; Polydorides AD; Niakan J; Chehade M
Am J Surg Pathol; 2017 May; 41(5):616-621. PubMed ID: 28296675
[TBL] [Abstract][Full Text] [Related]
29. A randomized, double-blinded, placebo-controlled study of the use of viscous oral cromolyn sodium for the treatment of eosinophilic esophagitis.
Lieberman JA; Zhang J; Whitworth J; Cavender C
Ann Allergy Asthma Immunol; 2018 May; 120(5):527-531. PubMed ID: 29544738
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and Safety of Monoclonal Antibodies for the Treatment of Eosinophilic Esophagitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
de Oliveira FD; Costa RC; de Santana Sato EDB; Khalil SM; Meine GC
Dig Dis Sci; 2024 May; ():. PubMed ID: 38709421
[TBL] [Abstract][Full Text] [Related]
31. Pharmacological treatments for eosinophilic esophagitis: current options and emerging therapies.
Lucendo AJ
Expert Rev Clin Immunol; 2020 Jan; 16(1):63-77. PubMed ID: 31842634
[No Abstract] [Full Text] [Related]
32. Recent Progress in the Research of Eosinophilic Esophagitis and Gastroenteritis.
Kinoshita Y; Ishimura N; Oshima N; Mikami H; Okimoto E; Jiao DJ; Ishihara S
Digestion; 2016; 93(1):7-12. PubMed ID: 26789117
[TBL] [Abstract][Full Text] [Related]
33. Immunohistochemical differentiation of eosinophilic esophageal myositis from eosinophilic esophagitis.
Sato H; Nakajima N; Hasegawa G; Kawata Y; Sato Y; Suzuki K; Honma T; Terai S
J Gastroenterol Hepatol; 2017 Jan; 32(1):106-113. PubMed ID: 27262491
[TBL] [Abstract][Full Text] [Related]
34. Loss of Endothelial TSPAN12 Promotes Fibrostenotic Eosinophilic Esophagitis via Endothelial Cell-Fibroblast Crosstalk.
Shoda T; Wen T; Caldwell JM; Ben-Baruch Morgenstern N; Osswald GA; Rochman M; Mack LE; Felton JM; Abonia JP; Arva NC; Atkins D; Bonis PA; Capocelli KE; Collins MH; Dellon ES; Falk GW; Gonsalves N; Gupta SK; Hirano I; Leung J; Menard-Katcher PA; Mukkada VA; Putnam PE; Rudman Spergel AK; Spergel JM; Wechsler JB; Yang GY; Aceves SS; Furuta GT; Rothenberg ME;
Gastroenterology; 2022 Feb; 162(2):439-453. PubMed ID: 34687736
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of oral budesonide suspension in pediatric patients with eosinophilic esophagitis.
Gupta SK; Vitanza JM; Collins MH
Clin Gastroenterol Hepatol; 2015 Jan; 13(1):66-76.e3. PubMed ID: 24907502
[TBL] [Abstract][Full Text] [Related]
36. Pattern of esophageal eosinophilic infiltration in patients with achalasia and response to Heller myotomy and Dor fundoplication.
Cools-Lartigue J; Chang SY; Mckendy K; Mayrand S; Marcus V; Fried GM; Ferri LE
Dis Esophagus; 2013; 26(8):766-75. PubMed ID: 22891632
[TBL] [Abstract][Full Text] [Related]
37. Serum eosinophil cationic protein is superior to mast cell tryptase as marker for response to topical corticosteroid therapy in eosinophilic esophagitis.
Schlag C; Pfefferkorn S; Brockow K; Haller B; Slotta-Huspenia J; Schulz S; von Werder A; Ring J; Schmid RM; Bajbouj M
J Clin Gastroenterol; 2014 Aug; 48(7):600-6. PubMed ID: 24177377
[TBL] [Abstract][Full Text] [Related]
38. CYP2C19 and STAT6 Variants Influence the Outcome of Proton Pump Inhibitor Therapy in Pediatric Eosinophilic Esophagitis.
Mougey EB; Williams A; Coyne AJK; Gutiérrez-Junquera C; Fernández-Fernández S; Cilleruelo ML; Rayo A; Echeverría L; Román E; González Lois C; Chao M; Al-Atrash H; Lima JJ; Franciosi JP
J Pediatr Gastroenterol Nutr; 2019 Nov; 69(5):581-587. PubMed ID: 31490856
[TBL] [Abstract][Full Text] [Related]
39. Biologic Therapies for Immunoglobulin E-mediated Food Allergy and Eosinophilic Esophagitis.
Otani IM; Nadeau KC
Immunol Allergy Clin North Am; 2017 May; 37(2):369-396. PubMed ID: 28366483
[TBL] [Abstract][Full Text] [Related]
40. MicroRNA signature in patients with eosinophilic esophagitis, reversibility with glucocorticoids, and assessment as disease biomarkers.
Lu TX; Sherrill JD; Wen T; Plassard AJ; Besse JA; Abonia JP; Franciosi JP; Putnam PE; Eby M; Martin LJ; Aronow BJ; Rothenberg ME
J Allergy Clin Immunol; 2012 Apr; 129(4):1064-75.e9. PubMed ID: 22391115
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
